RANI

Rani Therapeutics Holdings, Inc.

3.86 USD
+0.05 (+1.31%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rani Therapeutics Holdings, Inc. stock is down -26.48% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 June’s closed higher than May. 100% of analysts rate it a buy.

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly. RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis, RT-102, a parathyroid hormone that is in preclinical studies for osteoporosis.

  • Maxim Group
    Fri Jun 14, 09:10
    buy
    initial
  • Rodman & Renshaw
    Thu Jun 13, 13:34
    buy
    initial